Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen is a biotechnology company with a diverse pipeline of gene and cell therapies for retinal diseases and vaccines. Their recent Phase 2 trial for their modifier gene therapy platform has shown promising results with a 31% reduction in GA lesion area and a 27% reduction in EZ loss vs. controls. This could lead to a pivotal trial in the near future and potential FDA and EMA approvals. The company also has a partnership with Bharat Biotech for the COVAXIN SARS-CoV-2 vaccine, which has the potential to positively impact the company's financials and enhance their reputation in the industry. However, there are risks involved with clinical trials and regulatory approval, so careful monitoring of the company's progress is important.

Bears say

Ocugen is a company with cutting-edge gene and cell therapy platforms and promising clinical data, but it faces significant financing and competition risks. With limited revenue and a need for more funding, it may struggle to continue its development programs. Its success is also dependent on navigating a highly competitive market and securing strong partnerships. While it offers potential for significant upside if its clinical trials are successful and it can secure strategic collaborations or acquisitions, the financial and competitive challenges make it a risky investment at this time.

Ocugen, Inc. (OCGN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.